Together, these studies suggest that IL-5 is a promising yet under-investigated therapeutic target for obesity and metabolic diseases, primarily through approaches that enhance eosinophil activity rather than reduce it. Here, IL5 is linked to obesity due to melanocortin 4 receptor deficiency.